Scarica l'app Stockscreener
4.92
4.65%
-0.24
Dopo l'orario di chiusura:
4.68
-0.24
-4.88%
Precedente Chiudi:
$5.16
Aprire:
$5.16
Volume 24 ore:
26,098
Relative Volume:
0.15
Capitalizzazione di mercato:
$9.65M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-9.39%
1M Prestazione:
-34.83%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.8901
$5.2361
Intervallo di 1 settimana:
$4.8901
$5.43
Portata 52W:
$3.50
$8.86
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Confronta QNTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| QNTM | 4.92 | 9.65M | 0 | 0 | 0 | 0.00 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Quantum Biopharma Ltd Borsa (QNTM) Ultime notizie
Quantum BioPharma Ltd expected to post a loss of $3.90 a shareEarnings Preview - XM
Quantum BioPharma initiates phase 1 multiple sclerosis trial By Investing.com - Investing.com Canada
Quantum BioPharma sues CIBC and RBC seeking $700M in damages - MSN
Quantum BioPharma initiates phase 1 multiple sclerosis trial - Investing.com
Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia - AccessWire
InvestmentPitch Media Video Discusses FSD Pharma's New OTCQB Symbol and Appointment of Former U.S. Congressman Stephen Buyer to its Board of DirectorsVideo Available on Investmentpitch.com - Marketscreener.com
Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma - Marketscreener.com
Freedman Normand Friedland Files Market Manipulation Case On Behalf of Quantum Biopharma - PR Newswire
Quantum BioPharma Ltd - Stockhouse Publishing
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH - Marketscreener.com
Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spo - AccessWire
Quantum BioPharma posts link to lawsuit against CIBC World Markets, RBC Dominion - TipRanks
Quantum BioPharma alleges major market manipulation By Investing.com - Investing.com Australia
Quantum BioPharma sues over alleged stock spoofing - The Globe and Mail
Quantum BioPharma sues CIBC and RBC seeking $700M in damages | 2024-10-21 | Investing News - Stockhouse Publishing
Quantum BioPharma alleges major market manipulation - Investing.com
Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing - Chronicle-Tribune
Quantum BioPharma (QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700M - StreetInsider.com
Quantum BioPharma Ltd. (NASDAQ: QNTM): Pioneering Alcohol Metabolism Support with Unbuzzd - openPR
Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges - openPR
Quantum BioPharma Expands Market for Alcohol Metabolism Product Unbuzzd - Citybuzz
Celly Nu secures distribution for alcohol metabolism drink By Investing.com - Investing.com South Africa
Celly Nu secures distribution deal in the Caribbean By Investing.com - Investing.com South Africa
Celly Nu secures distribution deal in the Caribbean - Investing.com India
Celly Nu secures distribution for alcohol metabolism drink - Investing.com
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America - Newsfile
Quantum BioPharma Ltd. Pharma Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group Across Puerto Rico, the Caribbean, and Parts of Central and South America - WSIL TV
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and parts of Central and South America - AccessWire
Pre-market Movers: ALZN, VRAX, APDN, LQDA... - RTTNews
Quantum Biopharma Provides Corporate Update - GuruFocus.com
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US - Markets Insider
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Invesments and Kingswood US - Quantisnow
Investor.News Prepares for the ArcStone-Kingswood Growth Summit 2024 - InvestorNews Inc.
Quantum BioPharma Closes Private Placement Offering - Invezz
QUANTUM BIOPHAR (QNTM) Upgraded to Buy: Here's What You Should Know - MSN
Quantum BioPharma Ltd. announced that it has received CAD 0.000036 million in funding from Fortius Research and Trading Corporation, Xorax Family Trust - Marketscreener.com
Quantum BioPharma to run multiple sclerosis progression study | 2024-09-09 | Investing News - Stockhouse Publishing
Quantum BioPharma partners for multiple sclerosis study - Investing.com
S&P 500 Materials [Sector] (SRMA) QuotePress Release - The Globe and Mail
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis - Digital Journal
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease - PharmiWeb.com
Quantum Biopharma Ltd Azioni (QNTM) Dati Finanziari
Non sono disponibili dati finanziari per Quantum Biopharma Ltd (QNTM). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.79%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):